Oral meloxicam given as an ancillary treatment at respiratory disease diagnosis was not associated with growth, clinical scores, or ultrasound scores in preweaned dairy calves.

Objective: To assess the efficacy of a single dose of oral meloxicam as an ancillary therapy to an antibiotic given at the time of respiratory disease identification on average daily gain (ADG), behavioral attitude, clinical respiratory, and lung ultrasound scores in preweaned dairy calves. Animals: 215 male and female Holstein, Jersey, and crossbred preweaned calves enrolled between 1 and 14 days of age at study enrollment on a single commercial dairy in the western US. Methods: The study took place from March 4, 2021, to November 21, 2021. In this double-blind placebo-controlled study, calves were given an antibiotic (1.1 mL of tulathromycin/kg, SC, once) and either a placebo (1 mg of lactose monohydrate/kg, in a gelatin capsule) or oral meloxicam (1 mg/kg) at the time of respiratory disease identification. Behavioral attitude, clinical respiratory, and lung ultrasound scores and ADG were assessed in preweaned dairy calves at different time points including the next health examination, 1 week later, or at weaning. Results: There was no association between treatment (placebo vs meloxicam) on ADG or respiratory disease status at weaning (P > .05). There was no effect of treatment on behavioral attitude, clinical respiratory, or lung ultrasound scores at the next health examination or 1 week later (P > .05). Clinical Relevance: The present study did not provide evidence that oral meloxicam given once is beneficial for growth, behavioral attitude, or clinical or lung ultrasound scores.

Sensor analysis and initial assessment of detectable first hoof contacts and last break-overs as unique signal fluctuations for equine gait analysis.

The objective of the control study was to assess 2 prominent fluctuations in a single optical signal as being either a true first hoof contact or a last break-over based on descriptive measures. The study builds on initial findings from a preliminary investigation of the embedded-optical-base system's (EOBS) capabilities in signal capturing and feasibility as potential alternative to existing gait technologies, such as piezoelectric (e.g., load cell) systems. Hoof contacts and break-overs were measured (0 to 1 au; arbitrary units) using a 2.4-m (length) × 0.9-m (width) platform containing 1 EOBS. Three mixed-breed horses (n = 3) were injected with saline or either 100 IU or 200 IU Botox (i.e., onabotulinumtoxinA) with a 2.5-mL final volume. Injections were made into the deep digital flexor muscle at the motor end plates, with electromyography and ultrasound guidance. Horses were observed for 3 time points (pre-, post-, and recovery test days) over the span of a 4-mo period. Signal fluctuations [i.e., amplitude of hoof impacts based on true first hoof contacts (ΔS TS) and true last break-overs (ΔS TL)] and kinematics [i.e., complete gait pass (CGP) time duration (T)] were recorded from each horse. Visual observations and video analysis were used for determining gait pattern categories. Individual horse measurements were analyzed for each trial, compared with video data and classified. Comparison of primary signal fluctuations (i.e., ΔS TS vs. ΔS TL; forelimb vs. hindlimb) exhibited significant differences between hoof contacts and break-overs (P < 0.05). Right and left forelimb hoof contacts and hindlimb break-overs were not significantly different (P = 0.966; 0.063 ± 0.135; Estimate ± SE; P = 0.606; 0.176 ± 0.142; Estimate ± SE, respectively). Additionally, treatment vs. saline forelimbs did not exhibit significant difference (P = 0.7407; -0.098 ± 0.279; Estimate ± SE). Overall, data showed that the EOBS can collect repeatable and unique primary signal fluctuations as prominent and different gait measurements providing evidence to further development and research of the sensing system.